Inventor · disambiguated record
David A. Scott
Also filed as: SCOTT DAVID · SCOTT DAVID A
13 granted patents·7 pending applications·2 citations·filing 2016–2025
81Inventor score
Files withDANA FARBER CANCER INST INC12CHILDRENS MEDICAL CENTER3UNIV CORNELL3SCOTT DAVID A1UNIV ARIZONA1
Top patents by PatentIndex Score
20 records- 0175US11673891B2Imidazopyrimidine compounds and uses thereofDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 13, 2023·1 cites·19 claims
- 0275US2025340534A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0375US2025340535A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0472US12391671B2Allosteric EGFR inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2022·Granted Aug 19, 2025·0 cites·29 claims
- 0571US12268739B2Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune responseCHILDRENS MEDICAL CENTER·Filed 2019·Granted Apr 8, 2025·1 cites·18 claims
- 0670US2025325659A1Use of toll-like receptor 2 (tlr-2) agonist for modulating human immune responseCHILDRENS MEDICAL CENTER·Filed 2024·Application pending·0 cites
- 0764US2025388573A1Fused bicyclic egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 0863US11945816B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2021·Granted Apr 2, 2024·0 cites·16 claims
- 0955US11186574B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 30, 2021·0 cites·20 claims
- 1051US12161649B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Dec 10, 2024·0 cites·22 claims
- 1151US2023250094A1Small molecule inhibitors of tdp-43 activity and uses thereofUNIV ARIZONA·Filed 2021·Application pending·0 cites
- 1249US12377080B2Allosteric EGFR inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Granted Aug 5, 2025·0 cites·20 claims
- 1349US12318452B2Degraders of WEE1 kinaseDANA FARBER CANCER INST INC·Filed 2019·Granted Jun 3, 2025·0 cites·19 claims
- 1446US2022233545A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 1545US2023212171A1Allosteric egfr inhibitors and methods of use thereofSCOTT DAVID A·Filed 2021·Application pending·0 cites
- 1644US12365696B2Small-molecule focal adhesion kinase (FAK) inhibitorsDANA FARBER CANCER INST INC·Filed 2020·Granted Jul 22, 2025·0 cites·26 claims
- 1741US11248007B2Inhibitors of MALT1 and uses thereofUNIV CORNELL·Filed 2018·Granted Feb 15, 2022·0 cites·20 claims
- 1840US11730810B2Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune responseCHILDRENS MEDICAL CENTER·Filed 2018·Granted Aug 22, 2023·0 cites·26 claims
- 1938US10689366B2Compounds for MALT1 degredationUNIV CORNELL·Filed 2017·Granted Jun 23, 2020·0 cites·19 claims
- 2036US10711036B2MALT1 inhibitors and uses thereofUNIV CORNELL·Filed 2016·Granted Jul 14, 2020·0 cites·34 claims
Join the waitlist — get patent alerts
Get an alert when David A. Scott files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →